Compare FLOC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | CDNA |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | FLOC | CDNA |
|---|---|---|
| Price | $27.44 | $20.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.50 | $28.00 |
| AVG Volume (30 Days) | 583.4K | ★ 598.1K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $22.92 | $16.01 |
| Revenue Next Year | $8.59 | $11.31 |
| P/E Ratio | ★ $16.57 | $399.00 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $14.03 | $10.96 |
| 52 Week High | $27.50 | $23.24 |
| Indicator | FLOC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 70.72 | 51.42 |
| Support Level | $15.04 | $16.63 |
| Resistance Level | N/A | $21.42 |
| Average True Range (ATR) | 1.07 | 1.35 |
| MACD | 0.22 | -0.22 |
| Stochastic Oscillator | 93.82 | 48.05 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.